EyePoint, Inc. Common Stock EYPT
Analyst Ratings
- Consensus
- Moderate Buy — 5 Buy · 5 Hold · 0 Sell (10 analysts)
- Avg. Price Target
- $25.25 (+643.7% upside)
Key Stats
- Today's Range
- $3.08 – $3.42
- 50-Day Range
- $3.05 – $14.76
- 52-Week Range
- $3.05 – $19.11
- Volume
- 1.83 million shs
- Average Volume
- 3.48 million shs
- Market Cap
- $273.29 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.22%
- Days to Cover
- 2.36
About EyePoint, Inc. Common Stock
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Related Stocks
Compare head-to-head: EYPT vs WAT·EYPT vs RVTY·EYPT vs TXG·EYPT vs BIO
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.